CAMBRIDGE, Mass., Sept. 16 /PRNewswire-FirstCall/ -- Transkaryotic
Therapies, Inc. (Nasdaq: TKTX) today announced that the company will be
participating at the UBS Global Life Sciences Conference being held in New
York, NY September 22-25, 2003. TKT's presentation will be webcast live on
Tuesday, September 23, 2003 at 2:00 p.m. Eastern Time, and may be accessed on
the Internet at http://www.tktx.com under the Investor Information section. A
replay of the presentation will be available on TKT's website until October
25, 2003.
About TKT
TKT is a biopharmaceutical company developing therapeutics for the
treatment of rare genetic diseases caused by protein deficiencies. The company
currently markets one product, Replagal(TM) (agalsidase alfa) for the
treatment of Fabry disease in the European Union and certain other countries.
TKT is headquartered in Cambridge, Massachusetts and has a majority-owned
subsidiary in Sweden, TKT Europe-5S AB, which is responsible for European
sales and marketing activities of Replagal. Additional information on TKT is
available on the company's website at http://www.tktx.com.
Replagal(TM) is a trademark of Transkaryotic Therapies, Inc.
Contact:
Daniella M. Lutz
Corporate Communications Specialist
(617) 349-0205
SOURCE Transkaryotic Therapies, Inc.
 back to top
Related links:
http://www.tktx.com
Photo Notes:
NewsCom:
http://www.newscom.com/cgi-bin/prnh/19990913/TKTLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, 888-776-6555 or 212-782-2840
Company News On-Call:
http://www.prnewswire.com/comp/120657.html
CONTACT:
Daniella M. Lutz, Corporate Communications
Specialist of TKT, +1-617-349-0205
|
